Economic consequences of mandatory price re-registration for medicines from the high-cost nosology program
| Autor: | V. A. Krylov, D. T. Ugrekhelidze, A. V. Rudakova |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Finance
Decree education.field_of_study Government business.industry Population 030209 endocrinology & metabolism Budget impact Medical care 03 medical and health sciences 0302 clinical medicine Stock keeping unit Economic analysis 030212 general & internal medicine Business education Economic consequences |
| Zdroj: | Kachestvennaya klinicheskaya praktika. :27-33 |
| ISSN: | 2618-8473 2588-0519 |
| DOI: | 10.37489/2588-0519-2020-3-27-33 |
| Popis: | The Government Decree, approved in December 2019, required registration certificates holders of reference drugs, included in the essential drug list (EDL), submit applications for mandatory price re-registration. Drugs included in the high-cost nosology list (high-cost list) must be included in the EDL.Objective: to assess the budget impact of price re-registration for high-cost list drugs.Material and methods. The comparing economic analysis of high-cost nosology program before and after price re-registration based on the Government Decree N 1683 (effective from 16.12.2019). 125 reference stock keeping units (SKUs), included in the high-cost list, were evaluated.Results. The analysis showed, that after re-registration the prices of 66 SKUs will remain the same. The prices of 43 reference SKUs will be reduced after setting a single maximum selling price («equalization»). Prices for 16 SKUs will be reduced due to lower registered prices in the reference countries. Considering the contracts executed in 20192020, the budget of the high-cost program is up to 74.430 billion rubles, and after re-registration it will be equal to 64.162 billion rubles, so the savings will amount 10.267 billion (13.8 %). The main drivers of re-registration prices savings are: Advagraf (1.175 billion rubles), Elizaria (2.083 billion rubles) and Revlimid (2.247 billion rubles). Separately, we analyzed the consequences ofprices re-registration in the V-thgroup ofhigh-cost list, which are provided topatients with malignant neoplasms of lymphoid, hematopoietic and related tissues. It was calculated, that in 2019 the contracts for V-th group of high-cost list were signed for 19.217 billion rubles, and after the price re-registration for the purchase of the same number of drugs 16.762 billion rubles will be spent, so the savings from the price re-registration will amount to 2.455 billion rubles (12.8 %), among which 2.247 billion rubles will be provided by price re-registration of Revlimid.Conclusions. The pricing policy implemented in the Russian Federation is aimed at increasing the availability of highly effective medical care to the population of the Russian Federation and significantly reduces the burden on the budget of the healthcare system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|